Page last updated: 2024-11-10

droloxifene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3033767
CHEMBL ID487
CHEBI ID34731
SCHEMBL ID4842
MeSH IDM0115500

Synonyms (59)

Synonym
BIDD:ER0213
k-060
k-21060e
fk-435
droloxifene [usan:inn]
e-droloxifene
droloxifenum [latin]
trans-1-(4-beta-dimethylaminoethoxyphenyl)-1-(3-hydroxyphenyl)-2-phenylbut-1-ene
k 060
(e)-1-(4'-(2-dimethylaminoethoxy)phenyl)-1-(3'-hydroxyphenyl)-2-phenylbut-1-ene
(e)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol
k 060e
droloxifeno [spanish]
phenol, 3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-, (e)-
k 21060e
(e)-alpha-(para-(2-(dimethylamino)ethoxy)phenyl)-alpha'-ethyl-3-stilbenol (iupac)
(e)-alpha-(p-(2-(dimethylamino)ethoxy)phenyl)-alpha'-ethyl-3-stilbenol
D03911
droloxifene (usan/inn)
82413-20-5
droloxifene
3-hydroxytamoxifen
3-[(1e)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol
CHEMBL487
k060e
k060 ,
chebi:34731 ,
(e)-3-hydroxy tamoxifen
(e)-3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-phenol citrate
A840323
(e)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
droloxifenum
droloxifeno
ec 428-010-4
unii-0m67u6z98f
0m67u6z98f ,
AKOS015895449
phenol, 3-1-4-2-(dimethylamino)ethoxyphenyl-2-phenyl-1-butenyl-, (e)-
droloxifene [usan]
droloxifene [iarc]
droloxifene [mart.]
(e)-.alpha.-p-2-(dimethylamino)ethoxyphenyl-.alpha.'-ethyl-3-stilbenol
droloxifene [mi]
droloxifene [inn]
SCHEMBL4842
e-1-[4'-(2-dimethylaminoethoxy)-phenyl]-1-(3 '-hydroxyphenyl)-2-phenyl-1-butene
ZQZFYGIXNQKOAV-OCEACIFDSA-N
DTXSID9022441
3-hydroxytamoxifen (droloxifene)
ethylenediaminedihydroiodide
3-[(1e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl] phenol
HY-121149
Q27116249
3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
CS-0079544
82413-20-5 (free base)
(e)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
MS-26418
bdbm430671

Research Excerpts

Overview

Droloxifene (DROL) is a new antiestrogen which is used for the treatment of endocrine-responsive breast cancer in humans. It is a more effective inducer of TGF beta and a more potent growth inhibitor for estrogen responsive human breast cancer cells than tamoxifen and toremifene.

ExcerptReferenceRelevance
"Droloxifene (DRO) is a selective estrogen receptor modulator that prevents bone loss by inhibition of bone turnover associated with estrogen deficiency in both growing and aged female rats. "( Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.
Chen, HK; Chidsey-Frink, KL; Crawford, DT; Jee, WS; Ke, HZ; Pirie, CM; Qi, H; Simmons, HA; Thompson, DD, 1999
)
3.19
"Droloxifene is a tamoxifen derivative whose effects in the therapy of human breast cancer and postmenopausal osteoporosis have been studied widely. "( Apoptosis induced by droloxifene and c-myc, bax and bcl-2 mRNA expression in cultured luteal cells of rats.
Cao, L; Gu, ZP; Leng, Y, 2000
)
2.07
"Droloxifene seems to be an interesting new anti-estrogen which should be further exploited."( Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.
Gundersen, S; Haarstad, H; Kvinnsland, S; Mella, O; Raabe, N; Wist, E, 1992
)
2.45
"Droloxifene is a more effective inducer of TGF beta and a more potent growth inhibitor for estrogen responsive human breast cancer cells than tamoxifen and toremifene in vitro."( Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells.
Dickson, RB; Dietel, M; Knabbe, C; Lippman, ME; Schmahl, M; Zugmaier, G, 1991
)
1.24
"Droloxifene (DROL) is a new antiestrogen which is used for the treatment of endocrine-responsive breast cancer in humans. "( Pharmacological activities of droloxifene isomers.
Huber, HJ; Löser, R; Seibel, K,
)
1.86

Effects

Droloxifene has anti-implantation effects in rats. It has no effect on high density lipoprotein/triglyceride metabolism.

ExcerptReferenceRelevance
"Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity."( Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity.
Cao, L; Feng, Y; Huang, Y; Leng, Y; Shen, Y, 2005
)
2.07
"Droloxifene has anti-implantation effects in rats. "( Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity.
Cao, L; Feng, Y; Huang, Y; Leng, Y; Shen, Y, 2005
)
2.07
"Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity."( Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity.
Cao, L; Feng, Y; Huang, Y; Leng, Y; Shen, Y, 2005
)
2.07
"Droloxifene has estrogen agonistic properties regarding low density lipoprotein and lipoprotein(a) metabolism, certain coagulation factors, and endothelium-dependent vasodilation but, unlike estrogen, has no effect on high density lipoprotein/triglyceride metabolism and the fibrinolytic cascade."( Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women.
Brinton, EA; Brosnihan, KB; Herrington, DM; MacLean, DB; Pusser, BE; Riley, WA; Thuren, TY, 2000
)
1.33

Treatment

ExcerptReferenceRelevance
"Droloxifene treatment had no significant influence on plasma levels of Oe2."( Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.
Geisler, J; Gundersen, S; Haarstad, H; Kvinnsland, S; Lønning, PE; Raabe, N, 1995
)
1.25

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were not significantly different between premenopausal and postmenopausal patients."( Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients.
Esumi, Y; Hata, T; Ninomiya, S; Sawamoto, T; Sekiguchi, M; Sugai, S; Tanaka, Y,
)
0.45

Compound-Compound Interactions

ExcerptReferenceRelevance
"To study the correlation of the reversal effect of tetrandrine (Tet) in combination with droloxifene (DRL) on multidrug resistant cell line K562/A02 and induction apoptosis, the apoptosis of K562 cells and K562/A02 cells after the treatment of Tet and DRL alone or their combination was detected by flow cytometry (FCM)."( [Reversal effect of tetrandrine in combination with droloxifene on cell line K562/A02 and its correlation with inducted apoptosis].
Chen, BA; Cheng, J; Dong, Y; Gao, F; Sheng, M; Wang, T; Zhang, P; Zhou, Y, 2004
)
0.8
"To observe the effect of Tetrandrine (tet) combined with Droloxifen (DRL) on the expression of bcr/abl mRNA and P(210) BCR/ABL protein of K562 cell line, after K562 cells were cultured in the medium containing Tet (1 micromol/L), DRL (5 micromol/L) separately or in their combination for some time, the changes of bcr/abl mRNA and protein expression were detected by RT-PCR and Western blot respectively."( [Effect of tetrandrine combined with Droloxifen on the expression of bcr/abl of K562 at both mRNA and protein levels].
Chen, BA; Cheng, J; Gao, F; Qian, XJ, 2005
)
0.33
"The aim of this study was to investigate the mechanism to reverse the drug resistance of leukemia cells in tetrandrine (Tet) alone or in combination with droloxifen (Drol) by using protein chips and to lay the theoretical basis for the clinical applications."( [Using protein chips to study mechanism underlying reversion of drug resistance in leukemia cells in tetrandrine alone or in combination with droloxifene].
Chen, BA; Cheng, J; Du, J; Gao, F; Lu, ZH; Zhang, CX, 2005
)
0.53
"To study the effect of tetrandrine (Tet) in combination with droloxifen (DRL) on the expression of nuclear factor kappa B (NF-kappaB) in K562 and K562/A02 cell lines and its reversal mechanism."( [Effect of tetrandrine in combination with droloxifen on the expression of NF-kappaB protein in K562 and K562/A02 cell lines].
Chen, BA; Chen, NN; Cheng, HY; Cheng, J; Ding, JH; Gao, C; Gao, F; Huang, CY; Shen, HL; Su, AL; Sun, XC; Sun, YY; Wang, J; Xu, WL; Zhao, G; Zhao, HH, 2008
)
0.35

Bioavailability

Single oral doses of a solution formulation of (14)C-droloxifene citrate (141 mg) appeared to be rapidly and well absorbed in four post-menopausal female subjects. First-pass hepatic extraction is approximately 70-80% following an oral dose of 1 mg/kg.

ExcerptReferenceRelevance
" The bioavailability was 8% in mice, 18% in rats and 11% in monkeys due to extensive first-pass metabolism."( Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients.
Esumi, Y; Hata, T; Ninomiya, S; Sawamoto, T; Sekiguchi, M; Sugai, S; Tanaka, Y,
)
0.45
" Our findings suggest that the intestine is neither a metabolic nor an absorptive barrier to the bioavailability of droloxifene in the female Sprague-Dawley rat and that first-pass hepatic extraction is approximately 70-80% following an oral dose of 1 mg/kg."( First-pass metabolism and biliary recirculation of droloxifene in the female Sprague-Dawley rat.
Nickerson, DF; Tess, DA; Toler, SM, 1997
)
0.76
" Our findings suggest that hepatic first-pass metabolism may have been saturated following intraperitoneal drug administration due to the rapid rate of absorption and the corresponding high drug concentrations achieved."( Intraperitoneal and intraportal administration of droloxifene to the Sprague-Dawley rat: assessing the first-pass effect.
Nickerson, DF; Toler, SM, 1997
)
0.55
" Single oral doses of a solution formulation of (14)C-droloxifene citrate (141 mg) appeared to be rapidly and well absorbed in four post-menopausal female subjects."( Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects.
Baldock, GA; Brodie, RR; Chasseaud, LF; Jank, P; John, BA; McBurney, A; Von Nieciecki, A, 2002
)
0.81

Dosage Studied

ExcerptRelevanceReference
" In OVX rats treated with DRO, body weight decreased significantly in a dose-response manner, and total serum cholesterol was significantly reduced by 65% to 70% compared to both sham and OVX controls."( Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Chen, HK; Jee, WS; Ke, HZ; Ma, YF; Pirie, CM; Qi, H; Simmons, HA; Thompson, DD, 1995
)
0.68
" This fact permits the use of high Drol Z dosage in order to achieve a relevant modulating effect in vivo and to use this drug in combination with a further modulator so as to reach maximum efficacy with tolerable side effects."( In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.
Gieseler, F; Gullis, E; Hasmann, M; Löser, R; Nüssler, V; Pelka-Fleisc, R; Stötzer, O; Wilmanns, W; Zwierzina, H, 1998
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)6.60000.00022.45859.9600AID1804171
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID69386Percent inhibition of [3H]estradiol binding to cytoplasmic estrogen receptor of rat uterus1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID681359TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells1994Biochemical pharmacology, Jul-19, Volume: 48, Issue:2
Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID102418Effect of compound with 10e-8 M estradiol on the growth of MCF-7 cells at a concentration 10 e-7 M, percentage of control value being 901985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID170810Anti-uterotrophic effect in rats at 50 ug/animal/day in the presence of 0.5 ug estradiol benzoate1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID102429Effect on the growth of MCF-7 cells at a concentration of 10 e-7 M, percentage of control value being 671985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID102425Effect of compound with 10e-8 M estradiol on the growth of MCF-7 cells at a concentration of 10 e-6 M, percentage of control value being 681985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID102414Effect of compound on the growth of MCF-7 cells at a concentration of 10 e-6 M, percentage of control value being 351985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID191709Uterotrophic effect in rats at 50 ug/animal/day hydroxytamoxifen1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (107)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (13.08)18.7374
1990's67 (62.62)18.2507
2000's24 (22.43)29.6817
2010's1 (0.93)24.3611
2020's1 (0.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.50 (24.57)
Research Supply Index4.94 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (17.80%)5.53%
Reviews14 (11.86%)6.00%
Case Studies1 (0.85%)4.05%
Observational0 (0.00%)0.25%
Other82 (69.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]